Shicheng Guo

Publications (11) View all

• Article: Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer.

  Yangxing Zhao, Huafu Zhou, Kelong Ma, Jinfeng Sun, Xu Feng, Junfeng Geng, Jun Gu, Wei Wang, Hongyu Zhang, Yinghua He, Shicheng Guo, Xiaoyu Zhou, Jian Yu, Qiang Lin
  [show abstract] [hide abstract]
  ABSTRACT: To identify novel abnormally methylated genes in early stage non-small cell lung cancer (NSCLC), we analyzed the methylation status of 13 genes (ALX1, BCL2, FOXL2, HPP1, MYF6, OC2, PDGFRA, PHOX2A, PITX2, RARB, SIX6, SMPD3 and SOX1) in cancer tissues from 101 cases of stage I NSCLC patients and lung tissues from 30 cases of non-cancerous lung disease controls, using methylation-specific PCR (MSP). The methylation frequencies (29.70-64.36%) of 7 genes (MYF6, SIX6, SOX1, RARB, BCL2, PHOX2A and FOLX2) in stage I NSCLC were significantly higher compared with those in non-cancerous lung disease controls (P<0.05). The co-methylation of SIX6 and SOX1, or the co-methyaltion of SIX6, RARB and SOX1 was associated with adenosquamous carcinoma (ADC), and the co-methylation of BCL2, RARB and SIX6 was associated with smoking. A panel of 4 genes (MYF6, SIX6, BCL2 and RARB) may offer a sensitivity of 93.07% and a specificity of 83.33% in the diagnosis of stage I NSCLC. Furthermore, we also detected the expression of 8 pathological markers (VEGF, HER-2, P53, P21, EGFR, CHGA, SYN and EMA) in cancer tissues of stage I NSCLC by immunohistochemistry, and found that high expression levels of p53 and CHGA were associated with the methylation of BCL2 (P=0.025) and PHOX2A (P=0.023), respectively. In this study, among the 7 genes which demonstrated hypermethylation in stage I NSCLC compared with non-cancerous lung diseases, 5 genes (MYF6, SIX6, PHOX2A, FOLX2 and SOX1) were found for the first time to be abonormally methylated in NSCLC. Further study of these genes shed light on the carcinogenesis of NSCLC.
  Oncology letters 04/2013; 5(4):1211-1218. · 0.11 Impact Factor
• Article: Prognostic Role of MicroRNA-181a/b in Hematological Malignancies: A Meta-Analysis.

  Shenglong Lin, Lili Pan, Shicheng Guo, Junjie Wu, Li Jin, Jiu-Cun Wang, Shaoyuan Wang
  [show abstract] [hide abstract]
  ABSTRACT: Emerging evidence has shown that miRNAs participate in human carcinogenesis as tumor suppressors or oncogenes, and have prognostic value for patients with cancers. In recent years, the miR-181 family was found dysregulated in a variety of human cancers and significantly associated with clinical outcome of cancerous patients. MiR-181a and miR-181b (miR-181a/b) were the most investigated members in the family. However, the results of miR-181a/b from different studies were inconsistent. Therefore, we performed a meta-analysis to summarize all the results from available studies, aiming to delineate the prognostic role of miR-181a/b in human cancers. The identified articles were retrieved from the two main on-line databases, PubMed and EMBASE. We extracted and estimated the hazard ratios (HRs) for overall survival (OS), which compared the high and low expression levels of miR-181a/b in patients of the available studies. Each individual HR was used to calculate the pooled HR. Eleven studies of 1252 patients were selected into the final meta-analysis after a strict filtering and qualifying process. Fixed model or random model method was chosen depending on the heterogeneity between the studies. The subgroup analysis showed that high expressed miR-181a/b could prolong OS in patients with hematological malignancies rather than low expression level (HR = 0.717, P<0.0001). But the expression of miR-181a/b was not significantly relative to OS in patients with various cancers (HR = 0.861, p = 0.356). Our study indicates that the expression level of miR-181a/b is significantly associated with OS in hematological malignancies and can be an important clinical prognostic factor for those patients.
  PLoS ONE 01/2013; 8(3):e59532. · 4.09 Impact Factor
• Source

  Available from: Shicheng Guo

  Article: Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.

  Junjie Wu, Jie Liu, Yuhao Zhou, Jun Ying, Houdong Zou, Shicheng Guo, Lei Wang, Naiqing Zhao, Jianjun Hu, Daru Lu, Li Jin, Qiang Li, Jiu-Cun Wang
  [show abstract] [hide abstract]
  ABSTRACT: Published data have shown conflicting results about the relationship between X-ray repair cross-complementing group 1 (XRCC1) gene polymorphisms (Arg399Gln and Arg194Trp) and clinical outcome of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). A meta-analysis is needed to provide a systematic review of the published findings. We conducted a systematic review and meta-analysis to evaluate the predictive value of XRCC1 gene polymorphisms on clinical outcome up to October 1, 2010. The quality of each study was scored on the basis of predefined criteria. A total of 13 eligible follow-up studies met all the inclusion criteria. The XRCC1194Trp allele was found to be significantly associated with a favorable response rate relative to 194Arg [Trp vs. Arg: OR, 1.88; 95% confidence interval (CI), 1.48-2.38]. XRCC1399Gln was less favorably associated with both response rate (Gln vs. Arg: OR, 0.67; 95% CI, 0.52-0.87) and overall survival (Gln vs. Arg: HR, 1.30; 95% CI, 1.04-1.63) than 399Arg in analyses using all available studies; but these associations became insignificant when only high-quality studies were used. These findings suggest a predictive role for XRCC1 gene polymorphisms in clinical outcome. However, the role of 399Gln could be considered controversial because its impact on clinical outcome was insignificant in high-quality studies. These findings show the importance of establishing suitable criteria, including genetic epidemiologic, phenotypic, and clinical criteria, to improve quality control of study design and methods in pharmacogenomic studies related to XRCC1 gene polymorphism.
  Clinical Cancer Research 06/2012; 18(14):3972-81. · 7.74 Impact Factor
• Source

  Available from: Shicheng Guo

  Article: Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population.

  Yangxing Zhao, Shicheng Guo, Jinfeng Sun, Zhaohui Huang, Tongyu Zhu, Hongyu Zhang, Jun Gu, Yinghua He, Wei Wang, Kelong Ma, Jina Wang, Jian Yu
  [show abstract] [hide abstract]
  ABSTRACT: There is a need to supplement or supplant the conventional diagnostic tools, namely, cystoscopy and B-type ultrasound, for bladder cancer (BC). We aimed to identify novel DNA methylation markers for BC through genome-wide profiling of BC cell lines and subsequent methylation-specific PCR (MSP) screening of clinical urine samples. The methyl-DNA binding domain (MBD) capture technique, methylCap/seq, was performed to screen for specific hypermethylated CpG islands in two BC cell lines (5637 and T24). The top one hundred hypermethylated targets were sequentially screened by MSP in urine samples to gradually narrow the target number and optimize the composition of the diagnostic panel. The diagnostic performance of the obtained panel was evaluated in different clinical scenarios. A total of 1,627 hypermethylated promoter targets in the BC cell lines was identified by Illumina sequencing. The top 104 hypermethylated targets were reduced to eight genes (VAX1, KCNV1, ECEL1, TMEM26, TAL1, PROX1, SLC6A20, and LMX1A) after the urine DNA screening in a small sample size of 8 normal control and 18 BC subjects. Validation in an independent sample of 212 BC patients enabled the optimization of five methylation targets, including VAX1, KCNV1, TAL1, PPOX1, and CFTR, which was obtained in our previous study, for BC diagnosis with a sensitivity and specificity of 88.68% and 87.25%, respectively. In addition, the methylation of VAX1 and LMX1A was found to be associated with BC recurrence. We identified a promising diagnostic marker panel for early non-invasive detection and subsequent BC surveillance.
  PLoS ONE 01/2012; 7(4):e35175. · 4.09 Impact Factor
• Source

  Available from: Shicheng Guo

  Article: Quantitative assessment of the variation in IGF2BP2 gene and type 2 diabetes risk.

  Jie Wu, Junjie Wu, Yuhao Zhou, Houdong Zou, Shicheng Guo, Jie Liu, Liwen Lu, Hao Xu
  [show abstract] [hide abstract]
  ABSTRACT: Insulin-like growth factor 2 mRNA-binding protein 2 (IFG2BP2) belongs to an mRNA-binding protein family involved in the development and stimulation of insulin action, which has attracted considerable attention as a candidate gene for type 2 diabetes (T2D) since it was first identified through genome-wide association approach. The relationship between IFG2BP2 and T2D has been reported in various ethnic groups; however, these studies have yielded contradictory results. To investigate this inconsistency, we performed a meta-analysis of 35 studies involving a total of 175,965 subjects for two wildly studied polymorphisms (rs4402960 and rs1470579) of the IFG2BP2 to evaluate the effect of IFG2BP2 on genetic susceptibility for T2D. An overall random-effects per-allele OR of 1.13 (95% CI: 1.12-1.15; P < 10(-5)) and 1.09 (95% CI: 1.07-1.12; P < 10(-5)) was found for the two variants, respectively. Significant results were also observed using dominant or recessive genetic model. No significant results between study heterogeneity were found in most of the comparison. In the subgroup analysis by ethnicity, sample size, diagnostic criterion and mean age and BMI of cases, significantly increased risks were found for these polymorphisms in almost all genetic models. This meta-analysis demonstrated that these two common polymorphisms is a risk factor for developing T2D, but these associations vary in different ethnic populations.
  Acta Diabetologica 10/2011; · 2.78 Impact Factor